Self-assembled peptide nanoparticles responsive to multiple tumor microenvironment triggers provide highly efficient targeted delivery and release of antitumor drug

2019 ◽  
Vol 316 ◽  
pp. 196-207 ◽  
Author(s):  
Xinglu Jiang ◽  
Xiaobo Fan ◽  
Wei Xu ◽  
Chenggui Zhao ◽  
Hailu Wu ◽  
...  
2014 ◽  
Vol 177 ◽  
pp. 11-19 ◽  
Author(s):  
Ying Zhao ◽  
Tianjiao Ji ◽  
Hai Wang ◽  
Suping Li ◽  
Yuliang Zhao ◽  
...  

2021 ◽  
Vol 4 (2) ◽  
pp. 1499-1507
Author(s):  
Chunxiao Li ◽  
Zhenyu Chen ◽  
Dan Zheng ◽  
Jingyang Zhao ◽  
Jiandu Lei

Nano Today ◽  
2021 ◽  
Vol 38 ◽  
pp. 101119
Author(s):  
Masoud Delfi ◽  
Rossella Sartorius ◽  
Milad Ashrafizadeh ◽  
Esmaeel Sharifi ◽  
Yapei Zhang ◽  
...  

Nanoscale ◽  
2018 ◽  
Vol 10 (46) ◽  
pp. 21671-21680 ◽  
Author(s):  
Wenbin Li ◽  
Jianfeng Huang ◽  
Liangliang Feng ◽  
Liyun Cao ◽  
Shuwei He

The decreasing crystallinity of VS4 microspheres greatly increases the surface active sites, and then promotes the pseudocapacitive behavior, and finally leads to the high capacity, long cycling life and high rate capability.


2020 ◽  
Vol 6 (3) ◽  
pp. eaax5032 ◽  
Author(s):  
Kuan-Wei Huang ◽  
Fu-Fei Hsu ◽  
Jiantai Timothy Qiu ◽  
Guann-Jen Chern ◽  
Yi-An Lee ◽  
...  

While immunotherapy holds great promise for combating cancer, the limited efficacy due to an immunosuppressive tumor microenvironment and systemic toxicity hinder the broader application of cancer immunotherapy. Here, we report a combinatorial immunotherapy approach that uses a highly efficient and tumor-selective gene carrier to improve anticancer efficacy and circumvent the systemic toxicity. In this study, we engineered tumor-targeted lipid-dendrimer-calcium-phosphate (TT-LDCP) nanoparticles (NPs) with thymine-functionalized dendrimers that exhibit not only enhanced gene delivery capacity but also immune adjuvant properties by activating the stimulator of interferon genes (STING)–cGAS pathway. TT-LDCP NPs delivered siRNA against immune checkpoint ligand PD-L1 and immunostimulatory IL-2–encoding plasmid DNA to hepatocellular carcinoma (HCC), increased tumoral infiltration and activation of CD8+ T cells, augmented the efficacy of cancer vaccine immunotherapy, and suppressed HCC progression. Our work presents nanotechnology-enabled dual delivery of siRNA and plasmid DNA that selectively targets and reprograms the immunosuppressive tumor microenvironment to improve cancer immunotherapy.


2018 ◽  
Vol 90 (22) ◽  
pp. 13188-13192 ◽  
Author(s):  
Xueli Zhu ◽  
Hongyan Ye ◽  
Jin-Wen Liu ◽  
Ru-Qin Yu ◽  
Jian-Hui Jiang

Sign in / Sign up

Export Citation Format

Share Document